Skip to main content

Advertisement

SpringerLink
Log in

Commentary on the Endocrine Society Practice Guidelines: Consequences of adjustment of antihypertensive medication in screening of primary aldosteronism

Reviews in Endocrine and Metabolic Disorders Aims and scope Submit manuscript

Abstract

The Endocrine Society guidelines suggest to screen patients with primary aldosteronism (PA) free of hypertensive medications or alternatively to switch to drugs known to have minimal influence on the aldosterone to renin ratio (ARR). We retrospectively investigated the impact of such strategy on clinical outcome. 25 patients with PA and 25 with essential hypertension (EH) were studied. Initially all subjects were evaluated biochemically and received if possible an adjustment of their medication following the guidlines. Mineralocorticoid antagonists were discontinued in all subjects. Only 26 of 50 patients could be studied under optimal conditions (drug free or on medication with minimal influence on ARR) whereas the remaining 24 subjects had to receive additional drugs (such as ACE inhibitor, angiotensin-2 receptor blocker, or betablockers) because of initial blood pressure or comorbidities. Every fifth patient with a switch of the medication experienced a significant increase in blood pressure. 13 of 25 of PA patients needed potassium supplementation (105+/−25 mEq per day; range 8–320 mEq). Nine of these patients remained hypokalemic despite substitution (serum K 2.82+/−0.07 mmol/l), with 7 classified severely hypokalemic (<.3.0). We observed 6 serious adverse events requiring hospitalization including hypertensive crisis (n = 3), atrial fibrillation (n = 1), heart failure (n = 1) and ICD triggered electric shock (n = 1). In conclusion, in our experience the adjustment of the antihypertensive treatment during screening for PA is only possible in approximately half of patients and can cause severe side effect. Such recommendation, therefore, must include a note of caution because of possibly deleterious side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Mulatero P et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89(3):1045–50.

    Article  PubMed  CAS  Google Scholar 

  2. Padfield PL. Prevalence and role of a raised aldosterone to renin ratio in the diagnosis of primary aldosteronism: a debate on the scientific logic of the use of the ratio in practice. Clin Endocrinol (Oxf). 2003;59(4):422–6.

    Article  CAS  Google Scholar 

  3. Tiu SC et al. The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. J Clin Endocrinol Metab. 2005;90(1):72–8.

    Article  PubMed  CAS  Google Scholar 

  4. Montori VM, Young Jr WF. Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrinol Metab Clin North Am. 2002;31(3):619–32. xi.

    Article  PubMed  CAS  Google Scholar 

  5. Lim PO, MacDonald TM. Primary aldosteronism, diagnosed by the aldosterone to renin ratio, is a common cause of hypertension. Clin Endocrinol (Oxf). 2003;59(4):427–30.

    Article  CAS  Google Scholar 

  6. Mulatero P et al. Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends Endocrinol Metab. 2005;16(3):114–9.

    Article  PubMed  CAS  Google Scholar 

  7. Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem. 2005;51(2):386–94.

    Article  PubMed  CAS  Google Scholar 

  8. Tomaschitz A, Pilz S. Aldosterone to renin ratio—a reliable screening tool for primary aldosteronism? Horm Metab Res. 2010;42(6):382–91.

    Article  PubMed  CAS  Google Scholar 

  9. Jansen PM, Boomsma F, van den Meiracker AH. Aldosterone-to-renin ratio as a screening test for primary aldosteronism—the Dutch ARRAT Study. Neth J Med. 2008;66(5):220–8.

    PubMed  CAS  Google Scholar 

  10. Funder JW et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(9):3266–81.

    Article  PubMed  CAS  Google Scholar 

  11. Hannemann A et al. Reference intervals for aldosterone, renin, and the aldosterone-to-renin ratio in the population-based Study of Health in Pomerania (SHIP-1). Horm Metab Res. 2010;42(6):392–9.

    Article  PubMed  CAS  Google Scholar 

  12. Seifarth C et al. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol (Oxf). 2002;57(4):457–65.

    Article  CAS  Google Scholar 

  13. Mulatero P et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension. 2002;40(6):897–902.

    Article  PubMed  CAS  Google Scholar 

  14. Seiler L et al. Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication. Eur J Endocrinol. 2004;150(3):329–37.

    Article  PubMed  CAS  Google Scholar 

  15. Gallay BJ et al. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis. 2001;37(4):699–705.

    Article  PubMed  CAS  Google Scholar 

  16. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol. 2007;3(9):486–92.

    Article  PubMed  CAS  Google Scholar 

  17. Seiler L, Reincke M. The aldosterone to Renin ratio in secondary hypertension. Herz. 2003;28(8):686–91.

    Article  PubMed  Google Scholar 

  18. Montori VM et al. Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clin Proc. 2001;76(9):877–82.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure statement

The authors have nothing to disclose.

Author information

Authors and Affiliations

  1. Medizinische Klinik, Ludwig-Maximilians-Universität München, München, Germany

    Evelyn Fischer, Felix Beuschlein, Martin Bidlingmaier & Martin Reincke

  2. Medizinische Klinik—Innenstadt, Klinikum der Universität München, Ziemssenstr. 1, 80336, München, Germany

    Martin Reincke

Authors
  1. Evelyn Fischer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Felix Beuschlein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martin Bidlingmaier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Martin Reincke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Reincke.

Additional information

This work is supported by a grant of the Else Kröner-Fresenius-Stiftung to Martin Reincke

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fischer, E., Beuschlein, F., Bidlingmaier, M. et al. Commentary on the Endocrine Society Practice Guidelines: Consequences of adjustment of antihypertensive medication in screening of primary aldosteronism. Rev Endocr Metab Disord 12, 43–48 (2011). https://doi.org/10.1007/s11154-011-9163-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11154-011-9163-7

Keywords

Search

Navigation